The Role of RNAs in Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: 30 September 2024 | Viewed by 186
Special Issue Editor
Special Issue Information
Dear Colleagues,
Significant advances in RNA-based next-generation sequencing, single-cell transcriptomics, and third-generation long-read sequencing technologies have provided unprecedented depth and scope for understanding the role of RNA processing in diagnostics and leveraging potential new modes of therapies for undruggable targets in cancers. RNA-seq methods have led to the discovery of novel biomarkers in identifying differentially expressed miRNA, lncRNA, circRNA and fusion transcripts, enabling highly granular molecular characterizations of cancer subtypes that promise to actualize personalized medicine. Advances in separation science and nanotechnology platforms have helped to overcome some drawbacks of introducing RNA molecules into the body, such as the rapid degradation in human tissues; eliciting immunogenicity and Impermeability across membranes, promoting clinical trials for RNA-based therapeutics. A range of therapeutic options are being developed including: antisense oligonucleotide (ASO), small interfering RNA (siRNA), microRNA, aptamers, mRNA replacement and mRNA vaccines. This Special Issue reports on recent advances in RNA biology that will expand diagnostic and therapeutic capabilities for treating cancers.
Dr. Sanjive Qazi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- RNA biology
- next generation sequencing
- RNA based therapeutics personalized medicine
- nanotechnology
- cancers
